簡易檢索 / 詳目顯示

研究生: 趙涓含
Chao, Chuan-Han
論文名稱: 苦瓜三萜類化合物TCD對人類胃癌AGS細胞的抗腫瘤效應及增加化學治療的敏感性
TCD, a dietary triterpenoid, exerts anti-tumor activity and increases sensitivity of cisplatin in AGS human gastric adenocarcinoma cells
指導教授: 蔡帛蓉
Tsai, Po-Jung
學位類別: 碩士
Master
系所名稱: 人類發展與家庭學系
Department of Human Development and Family Studies
論文出版年: 2017
畢業學年度: 105
語文別: 中文
論文頁數: 82
中文關鍵詞: 胃癌順鉑三萜類化合物抑制增殖增強化療敏感
英文關鍵詞: gastric cancer, cisplatin, 3β, 7β, 25-trihydroxycucurbita-5, 23-dien-19-al, anti-proliferative, chemosensitizing effects
DOI URL: https://doi.org/10.6345/NTNU202203217
論文種類: 學術論文
相關次數: 點閱:163下載:0
分享至:
查詢本校圖書館目錄 查詢臺灣博碩士論文知識加值系統 勘誤回報
  • 先前文獻報導葫蘆烷三萜類化合物透過延滯細胞週期及促進細胞凋亡而抑制乳癌、子宮頸癌及前列腺癌的增生,並且也能夠增強子宮頸癌細胞KB-V1對化療藥物vinblastine和paclitaxel的敏感度。關於3β, 7β, 25-trihydroxycucurbita-5, 23-dien-19-al (TCD)對於胃癌細胞之影響的文獻報告卻相當有限,因此本研究以人類AGS胃癌細胞模式,探討自山苦瓜葉萃取純化分離的TCD對於抑制胃癌細胞增殖和增強AGS細胞對於順鉑(cisplatin)敏感度的效應。
    實驗結果顯示,由細胞存活率MTT分析及群落形成分析發現TCD (>20 µM) 單獨處理能顯著抑制AGS細胞增生與細胞聚落生成。由劉氏染色法觀察發現TCD改變AGS細胞的細胞核/細胞質比例和細胞型態,因此以流式細胞儀分析細胞凋亡(apoptotic assay)和細胞週期(cell cycle),發現30 µM TCD會將細胞週期延滯於G1期並引致細胞凋亡。以西方轉漬法觀察發現30 µM TCD造成AGS細胞凋亡相關蛋白caspase 9、caspase 3、和PARP表現量上升。另外觀察caspase酵素活性發現30 µM TCD能提高AGS細胞caspase 3活性。為觀察TCD是否具有增強cisplatin的藥效,合併使用IC20濃度的TCD (20 µM)與cisplatin (2 µM) 有效抑制AGS細胞增生且具協同作用(synergism)。在核質比及細胞型態的部分,cisplatin會使細胞脹大、DNA斷裂溢出細胞核,TCD會使細胞核聚縮並死亡,TCD/cisplatin併用時AGS細胞兼具上述特質。TCD/cisplatin (20 µM/ 2 µM)併用時顯著增加AGS細胞的凋亡比例,並顯著抑制cisplatin誘導之TNF-α mRNA表現。
    以AGS細胞異種移植模式,將裸鼠分為4組分別為控制組、TCD (20 mg/kg)組、cisplatin (4mg/kg)組和TCD/cisplatin併用組。給予藥物後經35天後觀察發現:和控制組比較,不論是單獨給予TCD或cisplatin和TCD/cisplatin併用都能顯著降低腫瘤體積和重量。於試驗第20~35天實驗期間TCD/cisplatin組的腫瘤體積平均值均低於其他3組,但僅於第30天和TCD組達統計上的顯著差異。然而投予TCD和TCD/cisplatin不會影響裸鼠體重和脾臟相對重量,但cisplatin組的體重和脾臟相對重量則顯著低於控制組和TCD組,因此推測TCD具有抑制AGS腫瘤生長的效用且副作用較低。
    綜論,在細胞實驗TCD可透過延滯細胞週期、引起細胞凋亡和抑制細胞增生,導致AGS細胞存活率下降。當TCD與cisplatin併用具有協同性的抑制AGS增殖的效果。在動物實驗TCD能抑制AGS腫瘤生長,顯示TCD具有協助治療胃癌的潛力,未來仍有待更多的研究以了解TCD的抗腫瘤作用機制與化療藥物併用的效果。
    關鍵字:胃癌、順鉑、三萜類化合物、抑制增殖、增強化療敏感

    Cucurbitane-type triterpenoids exert chemopreventive effects and cytotoxicities toward several cancer cells, such as prostate, cervical, and breast cancers. Kuguacin J, one of cucurbitane-type triterpenoids isolated from bitter melon, improved the sensitivity of chemotherapy drugs in cervical cancer cells. However, the knowledge concerning the anti-tumor effect of 3β, 7β, 25-trihydroxycucurbita-5, 23-dien-19-al (TCD) is limited. In the present study, we investigated the anti-proliferative and chemosensitizing effects of TCD, isolated from leaves of wild bitter melon, on human AGS gastric adenocarcinoma cells.
    AGS cells were treated with TCD alone or combined with cisplatin, a chemotherapeutic agent. Cell viability was assessed by MTT assay, cell cycle and apoptosis were assessed by flow-cytometric analysis, and the expression of major proteins regulating apoptosis was also detected. The results showed that TCD reduced cell viability, inhibited cell proliferation, and changed cellular morpgology of AGS cells. Flow cytometry revealed that TCD increased the sub-G1 population of of AGS cells. Treatment of TCD significantly increased caspase 3 activity. Western blotting showed that TCD treatment significantly increased the levels of pro-apoptotic proteins, including, caspase 9, caspase 3, and PARP, thus inducing apoptosis. It was also demonstrated that a combinational treatment of TCD and cisplatin synergistically inhibited cell growth and cisplatin-induced TNF-α expression, and increased apoptosis. Furthermore, a tumor xenograft model was generated by subcutaneous injection of AGS cells into the dorsum of nude mice. The growth of xenograft tumors was monitored and measured. Cisplatin (4mg/ kg·d), TCD (20 mg/ kg·d), or both combination significantly suppressed the tumor volume and weight from the 35th day after treatment, as compared to the vehicle control. However, the mice challenged with cisplatin showed body weight loss and splenic atrophy. No obvious damage to the organs was found in TCD group, indicating that TCD treatment (20 mg/ kg·d) showed no toxic effects. These findings suggested that the tumor-suppressing effect of TCD would be due to cell cycle inhibition, caspase activation and apotosis induction. TCD may be a promising candidate agent used in the treatment of gastric cancer.

    Key word: gastric cancer, cisplatin, 3β, 7β, 25-trihydroxycucurbita-5, 23-dien-19-al, anti-proliferative and chemosensitizing effects

    第一章、 文獻探討 1 第一節、 胃癌治療標的(Therapeutic targets in gastric cancer) 1 壹、 胃癌的罹患率與死亡率 1 貳、 胃癌分期(Classification of gastric cancer) 1 參、 罹患胃癌的風險因子與預防策略 2 一、 風險因子 2 二、 預防方法 5 第二節、 胃癌的治療方式(Therapeutic options of gastric cancer) 6 第三節、 化療抗藥性機轉(Drug Resistant Mechanisms) 8 第四節、 苦瓜的生理活性 14 壹、 苦瓜簡介 14 貳、 苦瓜萃取物之生物活性 14 一、 抗糖尿病 14 二、 抗肥胖與降血脂 15 三、 抗氧化 15 四、 抗發炎 16 五、 抗癌 16 參、 葫蘆烷型三萜類化合物(cucurbitane-type triterpenoids) 16 一、 抗糖尿病與調節脂質代謝 16 二、 抗發炎 17 三、 抗癌 17 第二章、 研究動機與目的 22 第三章、 材料方法 24 第一節、 山苦瓜葉萃取與純化 24 壹、 山苦瓜葉粗萃物與區分物製備 24 貳、 山苦瓜葉樣品純化 24 第二節、 細胞實驗 26 壹、 細胞培養 26 一、 AGS胃癌細胞 26 二、 細胞解凍及活化 26 三、 細胞繼代 26 四、 細胞冷凍保存 26 五、 細胞計數 26 貳、 細胞實驗方法 27 一、 細胞存活率分析(MTT assay) 27 二、 細胞群落形成分析(Cell Colony formation assay) 27 三、 劉氏染色法(Liu’s stain) 28 四、 碘化丙啶核酸染色(Propidium Iodide Nucleic Acid Stain) 28 五、 DNA斷裂分析(DNA fragmentation assay) 28 六、 細胞凋亡分析(Apoptosis assay) 29 七、 細胞週期分析(Cell cycle assay) 30 八、 caspase 3 活性分析(caspase 3 activity assay) 30 九、 西方點墨法(Western blot) 30 十、 定量聚合酶鏈鎖反應(Quantitative-Polymerase Chain Reaction, Q-PCR) 33 參、 研究材料 34 一、 藥品與試劑 34 二、 儀器設備及耗材 37 肆、 統計分析 38 第三節、 動物實驗 38 壹、 實驗動物飼養 38 貳、 動物犧牲與樣品收集 39 參、 統計分析 39 第四章、 結果 40 第一節、 TCD抑制人類胃癌AGS細胞的增殖 40 壹、 細胞存活率分析 40 一、 山苦瓜葉乙醇萃取物Fra.1~ Fra.5區分物對於AGS胃癌細胞存活率的影響 40 二、 TCD抑制AGS細胞生長 41 貳、 TCD對細胞聚落形成的影響 42 參、 以TCD處理AGS細胞後改變細胞型態 43 一、 TCD對AGS細胞型態的影響 43 二、 TCD對AGS細胞核型態(nuclear morphology)的影響 44 肆、 TCD對AGS細胞DNA斷裂(DNA fragmentation)的影響 45 伍、 TCD對細胞凋亡的影響 46 陸、 TCD對AGS細胞之細胞週期的影響 48 捌、 TCD對細胞凋亡相關蛋白表現的影響 50 第二節、 TCD合併cisplatin對於AGS胃癌細胞的影響 51 壹、 cisplatin合併TCD對於AGS胃癌細胞存活率的影響 51 貳、 cisplatin合併TCD對細胞型態、核質比及核酸的影響 53 參、 cisplatin合併TCD對細胞凋亡的影響 55 肆、 cisplatin合併TCD對發炎相關基因mRNA表現的影響 57 第三節、 TCD和cisplatin併用對於AGS 人類胃癌細胞異種移植的腫瘤生長的影響 58 壹、 體重、腫瘤體積變化與腫瘤重量 58 貳、 肝、腎、脾臟與肌肉相對重量變化 60 第五章、 討論與結論 62 第一節、 討論 62 壹、 山苦瓜萃取物的抗癌潛力 62 貳、 葫蘆烷型三萜類化合物與TCD的抗癌活性 63 參、 TCD提升AGS細胞對於cisplatin的敏感度 66 肆、 TCD抗腫瘤的潛力:in a xenograft model 68 第二節、 結論 70 第六章、 參考文獻 71

    台灣癌症登記中心。http://tcr.cph.ntu.edu.tw/uploadimages/Survival_98_102.pdf。12/30/2016
    全中和。2001。珍貴種源山苦瓜。花蓮區農業專訊,36 (6),5-7。
    全中和、林砡竹。(2008)。苦瓜新品種育成及 Gap 體系之建立。苦瓜產業與保健功效研討會刊,51-70。
    國家衛生研究院。(2012)。胃癌臨床診療指引。
    衛生福利部國民健康署。(2016)。中華民國102年癌症登記報告。
    Aggarwal, B.B., Prasad, S., Reuter, S., Kannappan, R., Yadev, V.R., Park, B., Kim, J.H., Gupta, S.C., Phromnoi, K., & Sundaram, C. (2011). Identification of novel anti-inflammatory agents from Ayurvedic medicine for prevention of chronic diseases:“reverse pharmacology” and “bedside to bench” approach. Current drug targets, 12(11), 1595.
    Agrawal, R., & Beohar, T. (2010). Chemopreventive and anticarcinogenic effects of Momordica charantia extract. Asian Pacific Journal of Cancer Prevention, 11(2), 371-375.
    Ahn, H.J., & Lee, D.S. (2015). Helicobacter pylori in gastric carcinogenesis. World Journal of Gastrointestinal Oncology, 7(12), 455-465. doi: 10.4251/wjgo.v7.i12.455
    Akihisa, T., Higo, N., Tokuda, H., Ukiya, M., Akazawa, H., Tochigi, Y., Kimura, Y., Suzuki, T., & Nishino, H. (2007). Cucurbitane-type triterpenoids from the fruits of Momordica charantia and their cancer chemopreventive effects. Journal of natural products, 70(8), 1233-1239.
    Alghasham, A.A. (2013). Cucurbitacins–a promising target for cancer therapy. International journal of health sciences, 7(1).
    Atmaca, A., Pauligk, C., Steinmetz, K., Altmannsberger, H.M., Jäger, E., & Al-Batran, S.E. (2011). Prognostic Impact of Phosphorylated Mitogen-Activated Protein Kinase Expression in Patients with Metastatic Gastric Cancer. Oncology, 80(1-2), 130-134.
    Bai, L.Y., Chiu, C.F., Chu, P.C., Lin, W.Y., Chiu, S.J., & Weng, J.R. (2016). A triterpenoid from wild bitter gourd inhibits breast cancer cells. Sci Rep, 6, 22419. doi: 10.1038/srep22419
    Bao, B., Chen, Y.-G., Zhang, L., Na Xu, Y.L., Wang, X., Liu, J., & Qu, W. (2013). Momordica charantia (Bitter Melon) Reduces Obesity-Associated Macrophage and Mast Cell Infiltration as well as Inflammatory Cytokine Expression in Adipose Tissues. PLOS ONE, 8(12), e84075. doi: 10.1371/journal.pone.0084075
    Bárbara Peleteiro & Nuno Lunet (2011). Role of Genetic and Environmental Risk Factors in Gastric Carcinogenesis Pathway, Gastritis and Gastric Cancer - New Insights in Gastroprotection, Diagnosis and Treatments, Dr. Paola Tonino (Ed.), InTech
    Chen, J.C., Chiu, M.H., Nie, R.L., Cordell, G.A., & Qiu, S.X. (2005). Cucurbitacins and cucurbitane glycosides: structures and biological activities. Nat Prod Rep, 22(3), 386-399. doi: 10.1039/b418841c
    Cheng, H.L., Kuo, C.Y., Liao, Y.W., & Lin, C.C. (2012). EMCD, a hypoglycemic triterpene isolated from Momordica charantia wild variant, attenuates TNF-alpha-induced inflammation in FL83B cells in an AMP-activated protein kinase-independent manner. Eur J Pharmacol, 689(1-3), 241-248. doi: 10.1016/j.ejphar.2012.05.033
    Cho, H.J., Baek, K.E., Park, S.-M., Kim, I.-K., Nam, I.-K., Choi, Y.-L., Park, S.-H., Im, M.-J., Choi, J., Ryu, J., Kim, J.W., Lee, C.W., Kang, S.S., & Yoo, J. (2011). RhoGDI2 confers gastric cancer cells resistance against cisplatin-induced apoptosis by upregulation of Bcl-2 expression. Cancer Letters, 311(1), 48-56. doi: http://dx.doi.org/10.1016/j.canlet.2011.06.024
    Chun, J., Joo, E.J., Kang, M., & Kim, Y.S. (2013). Platycodin D induces anoikis and caspase-mediated apoptosis via p38 MAPK in AGS human gastric cancer cells. J Cell Biochem, 114(2), 456-470. doi: 10.1002/jcb.24386
    Crew, K.D., & Neugut, A.I. (2006). Epidemiology of gastric cancer. World Journal of Gastroenterology, 12(3), 354. doi: 10.3748/wjg.v12.i3.354
    Cui, W., Yazlovitskaya, E.M., Mayo, M.S., Pelling, J.C., & Persons, D.L. (2000). Cisplatin‐induced response of c‐jun N‐terminal kinase 1 and extracellular signal‐regulated protein kinases 1 and 2 in a series of cisplatin‐resistant ovarian carcinoma cell lines. Molecular carcinogenesis, 29(4), 219-228.
    Dasari, S., & Tchounwou, P.B. (2014). Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol, 740, 364-378. doi: 10.1016/j.ejphar.2014.07.025
    El-Senduny, F.F., Badria, F.A., EL-Waseef, A.M., Chauhan, S.C., & Halaweish, F. (2016). Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B. Tumor Biology, 37(1), 685-698. doi: 10.1007/s13277-015-3773-8
    Escandell, J.M., Recio, M.C., Máñez, S., Giner, R.M., Cerdá-Nicolás, M., & Ríos, J.L. (2007). Cucurbitacin R Reduces the Inflammation and Bone Damage Associated with Adjuvant Arthritis in Lewis Rats by Suppression of Tumor Necrosis Factor-α in T Lymphocytes and Macrophages. Journal of Pharmacology and Experimental Therapeutics, 320(2), 581-590. doi: 10.1124/jpet.106.107003
    Fang, E.F., Zhang, C.Z.Y., Wong, J.H., Shen, J.Y., Li, C.H., & Ng, T.B. (2012a). The MAP30 protein from bitter gourd (Momordica charantia) seeds promotes apoptosis in liver cancer cells in vitro and in vivo. Cancer letters, 324(1), 66-74.
    Fang, E.F., Zhang, C.Z.Y., Zhang, L., Fong, W.P., & Ng, T.B. (2012b). In vitro and in vivo anticarcinogenic effects of RNase MC2, a ribonuclease isolated from dietary bitter gourd, toward human liver cancer cells. The international journal of biochemistry & cell biology, 44(8), 1351-1360.
    Fenoglio‐Preiser, C., Wang, J., Stemmermann, G., & Noffsinger, A. (2003). TP53 and gastric carcinoma: a review. Human mutation, 21(3), 258-270.
    Florea, A.M., & Busselberg, D. (2011). Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel), 3(1), 1351-1371. doi: 10.3390/cancers3011351
    Freedman, N.D., Abnet, C.C., Leitzmann, M.F., Mouw, T., Subar, A.F., Hollenbeck, A.R., & Schatzkin, A. (2007). A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol, 165(12), 1424-1433. doi: 10.1093/aje/kwm051
    Fulda, S., & Debatin, K.-M. (2004). Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. Oncogene, 23(40), 6702-6711.
    Gomceli, I., Demiriz, B., & Tez, M. (2012). Gastric carcinogenesis. World J Gastroenterol, 18(37), 5164-5170.
    Gu, K.-S., & Chen, Y. (2012). Mechanism of P-glycoprotein Expression in the SGC7901 Human Gastric Adenocarcinoma Cell Line Induced by Cyclooxygenase-2. Asian Pacific Journal of Cancer Prevention, 13(5), 2379-2383. doi: 10.7314/apjcp.2012.13.5.2379
    Hsu, Tsai, T.-H., Li, Y.-Y., Wu, W.-H., Huang, C.-J., & Tsai, P.-J. (2012a). Wild bitter melon (Momordica charantia Linn. var. abbreviata Ser.) extract and its bioactive components suppress Propionibacterium acnes-induced inflammation. Food Chemistry, 135(3), 976-984. doi: http://dx.doi.org/10.1016/j.foodchem.2012.05.045
    Hsu, H.Y., Lin, J.H., Li, C.J., Tsang, S.F., Tsai, C.H., Chyuan, J.H., Chiu, S.J., & Chuang, S.E. (2012b). Antimigratory Effects of the Methanol Extract from Momordica charantia on Human Lung Adenocarcinoma CL1 Cells. Evid Based Complement Alternat Med, 2012, 819632. doi: 10.1155/2012/819632
    Isobe, T., Aoyagi, K., Koufuji, K., Shirouzu, K., Kawahara, A., Taira, T., & Kage, M. (2013). Clinicopathological significance of hypoxia-inducible factor-1 alpha (HIF-1α) expression in gastric cancer. International Journal of Clinical Oncology, 18(2), 293-304. doi: 10.1007/s10147-012-0378-8
    Jayaprakasam, B., Seeram, N.P., & Nair, M.G. (2003). Anticancer and antiinflammatory activities of cucurbitacins from Cucurbita andreana. Cancer Lett, 189(1), 11-16.
    Kaur, M., Deep, G., Jain, A.K., Raina, K., Agarwal, C., Wempe, M.F., & Agarwal, R. (2013). Bitter melon juice activates cellular energy sensor AMP-activated protein kinase causing apoptotic death of human pancreatic carcinoma cells. Carcinogenesis, 34(7), 1585-1592. doi: 10.1093/carcin/bgt081
    Kaushik, U., Aeri, V., & Mir, S. (2015). Cucurbitacins - An insight into medicinal leads from nature. Pharmacognosy Reviews, 9(17), 12-18. doi: 10.4103/0973-7847.156314
    Kelley, J.R., & Duggan, J.M. (2003). Gastric cancer epidemiology and risk factors. Journal of Clinical Epidemiology, 56(1), 1-9. doi: 10.1016/s0895-4356(02)00534-6
    Kim, C.W., Lu, J.N., Go, S.I., Jung, J.H., Yi, S.M., Jeong, J.H., Hah, Y.S., Han, M.S., Park, J.W., Lee, W.S., & Min, Y.J. (2013). p53 restoration can overcome cisplatin resistance through inhibition of Akt as well as induction of Bax. Int J Oncol, 43(5), 1495-1502. doi: 10.3892/ijo.2013.2070
    Kubola, J., & Siriamornpun, S. (2008). Phenolic contents and antioxidant activities of bitter gourd (Momordica charantia L.) leaf, stem and fruit fraction extracts in vitro. Food chemistry, 110(4), 881-890.
    Kwatra, D., Dandawate, P., Padhye, S., & Anant, S. (2016). Bitter Melon as a Therapy for Diabetes, Inflammation, and Cancer: a Panacea? Current Pharmacology Reports, 2(1), 34-44. doi: 10.1007/s40495-016-0045-2
    Kwatra, D., Subramaniam, D., Ramamoorthy, P., Standing, D., Moran, E., Velayutham, R., Mitra, A., Umar, S., & Anant, S. (2013). Methanolic extracts of bitter melon inhibit colon cancer stem cells by affecting energy homeostasis and autophagy. Evidence-Based Complementary and Alternative Medicine, 2013.
    Lee-Huang, S., Huang, P.L., Sun, Y., Chen, H.C., Kung, H.F., & Murphy, W. (1999). Inhibition of MDA-MB-231 human breast tumor xenografts and HER2 expression by anti-tumor agents GAP31 and MAP30. Anticancer research, 20(2A), 653-659.
    Lee, C.K., Park, K.K., Lim, S.S., Park, J.H., & Chung, W.Y. (2007). Effects of the licorice extract against tumor growth and cisplatin-induced toxicity in a mouse xenograft model of colon cancer. Biol Pharm Bull, 30(11), 2191-2195.
    Lee, D.H., Iwanski, G.B., & Thoennissen, N.H. (2010). Cucurbitacin: ancient compound shedding new light on cancer treatment. ScientificWorldJournal, 10, 413-418. doi: 10.1100/tsw.2010.44
    Leung, L., Birtwhistle, R., Kotecha, J., Hannah, S., & Cuthbertson, S. (2009). Anti-diabetic and hypoglycaemic effects of Momordica charantia (bitter melon): a mini review. British Journal of Nutrition, 102(12), 1703-1708.
    Li, Tsang, S.F., Tsai, C.H., Tsai, H.Y., Chyuan, J.H., & Hsu, H.Y. (2012a). Momordica charantia Extract Induces Apoptosis in Human Cancer Cells through Caspase- and Mitochondria-Dependent Pathways. Evid Based Complement Alternat Med, 2012, 261971. doi: 10.1155/2012/261971
    Li, D., Zhang, Y., Xie, Y., Xiang, J., Zhu, Y., & Yang, J. (2013). Enhanced tumor suppression by adenoviral PTEN gene therapy combined with cisplatin chemotherapy in small-cell lung cancer. Cancer gene therapy, 20(4), 251-259.
    Li, M., Chen, Y., Liu, Z., Shen, F., Bian, X., & Meng, Y. (2009). Anti-tumor activity and immunological modification of ribosome-inactivating protein (RIP) from Momordica charantia by covalent attachment of polyethylene glycol. Acta Biochimica et Biophysica Sinica, 41(9), 792-799. doi: 10.1093/abbs/gmp068
    Li, Y., Tan, B., Zhao, Q., Fan, L.-Q., Liu, Y., Hao, Y.-J., & Zhao, X.-F. (2012b). Tumor chemosensitivity is correlated with expression of multidrug resistance associated factors in variously differentiated gastric carcinoma tissues. Hepato-gastroenterology, 60(121), 213-216.
    Lii, C.-K., Chen, H.-W., Yun, W.-T., & Liu, K.-L. (2009). Suppressive effects of wild bitter gourd (Momordica charantia Linn. var. abbreviata ser.) fruit extracts on inflammatory responses in RAW 264.7 macrophages. Journal of Ethnopharmacology, 122(2), 227-233. doi: http://dx.doi.org/10.1016/j.jep.2009.01.028
    Lin, Y., Shi, R., Wang, X., & Shen, H.-M. (2008). Luteolin, a flavonoid with potentials for cancer prevention and therapy. Current cancer drug targets, 8(7), 634-646.
    Liu, Zhang, M., Zhang, H., Sun, C., Yang, X., Deng, Y., & Ji, W. (2008a). Combined antitumor activity of cucurbitacin B and docetaxel in laryngeal cancer. Eur J Pharmacol, 587(1-3), 78-84. doi: 10.1016/j.ejphar.2008.03.032
    Liu, F.S. (2009). Mechanisms of chemotherapeutic drug resistance in cancer therapy--a quick review. Taiwan J Obstet Gynecol, 48(3), 239-244. doi: 10.1016/s1028-4559(09)60296-5
    Liu, L., Ning, X., Sun, L., Zhang, H., Shi, Y., Guo, C., Han, S., Liu, J., Sun, S., & Han, Z. (2008b). Hypoxia‐inducible factor‐1α contributes to hypoxia‐induced chemoresistance in gastric cancer. Cancer science, 99(1), 121-128.
    Liu, T., Peng, H., Zhang, M., Deng, Y., & Wu, Z. (2010). Cucurbitacin B, a small molecule inhibitor of the Stat3 signaling pathway, enhances the chemosensitivity of laryngeal squamous cell carcinoma cells to cisplatin. European Journal of Pharmacology, 641(1), 15-22. doi: 10.1016/j.ejphar.2010.04.062
    Mayne, S.T., Risch, H.A., Dubrow, R., Chow, W.-H., Gammon, M.D., Vaughan, T.L., Farrow, D.C., Schoenberg, J.B., Stanford, J.L., & Ahsan, H. (2001). Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiology Biomarkers & Prevention, 10(10), 1055-1062.
    Miller, R.P., Tadagavadi, R.K., Ramesh, G., & Reeves, W.B. (2010). Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel), 2(11), 2490-2518. doi: 10.3390/toxins2112490
    Mimori, K., Sadanaga, N., Yoshikawa, Y., Ishikawa, K., Hashimoto, M., Tanaka, F., Sasaki, A., Inoue, H., Sugimachi, K., & Mori, M. (2006). Reduced tau expression in gastric cancer can identify candidates for successful Paclitaxel treatment. British journal of cancer, 94(12), 1894-1897.
    Nam, S.Y., Lee, H.S., JUNG, G.A., Choi, J., Cho, S.J., Kim, M.K., Kim, W.H., & Lee, B.L. (2003). Akt/PKB activation in gastric carcinomas correlates with clinicopathologic variables and prognosis. Apmis, 111(12), 1105-1113.
    Nerurkar, P.V., Lee, Y.-K., & Nerurkar, V.R. (2010). Momordica charantia (bitter melon) inhibits primary human adipocyte differentiation by modulating adipogenic genes. BMC complementary and alternative medicine, 10(1), 1.
    Nerurkar, P.V., Lee, Y.K., Motosue, M., Adeli, K., & Nerurkar, V.R. (2008). Momordica charantia (bitter melon) reduces plasma apolipoprotein B-100 and increases hepatic insulin receptor substrate and phosphoinositide-3 kinase interactions. Br J Nutr, 100(4), 751-759. doi: 10.1017/S0007114508937430
    Nerurkar, P.V., Pearson, L., Efird, J.T., Adeli, K., Theriault, A.G., & Nerurkar, V.R. (2005). Microsomal triglyceride transfer protein gene expression and ApoB secretion are inhibited by bitter melon in HepG2 cells. J Nutr, 135(4), 702-706.
    Ohta, T., Ohmichi, M., Hayasaka, T., Mabuchi, S., Saitoh, M., Kawagoe, J., Takahashi, K., Igarashi, H., Du, B., & Doshida, M. (2006). Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models. Endocrinology, 147(4), 1761-1769.
    Oki, E., Baba, H., Tokunaga, E., Nakamura, T., Ueda, N., Futatsugi, M., Mashino, K., Yamamoto, M., Ikebe, M., Kakeji, Y., & Maehara, Y. (2005). Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. International Journal of Cancer, 117(3), 376-380. doi: 10.1002/ijc.21170
    Peek, R.M., & Blaser, M.J. (2002). Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer, 2(1), 28-37.
    Petronelli, A., Pannitteri, G., & Testa, U. (2009). Triterpenoids as new promising anticancer drugs. Anti-Cancer Drugs, 20(10), 880-892. doi: 10.1097/CAD.0b013e328330fd90
    Pitchakarn, Ogawa, K., Suzuki, S., Takahashi, S., Asamoto, M., Chewonarin, T., Limtrakul, P., & Shirai, T. (2010). Momordica charantia leaf extract suppresses rat prostate cancer progression in vitro and in vivo. Cancer science, 101(10), 2234-2240.
    Pitchakarn, Suzuki, S., Ogawa, K., Pompimon, W., Takahashi, S., Asamoto, M., Limtrakul, P., & Shirai, T. (2011). Induction of G1 arrest and apoptosis in androgen-dependent human prostate cancer by Kuguacin J, a triterpenoid from Momordica charantia leaf. Cancer Lett, 306(2), 142-150. doi: 10.1016/j.canlet.2011.02.041
    Pitchakarn, Suzuki, S., Ogawa, K., Pompimon, W., Takahashi, S., Asamoto, M., Limtrakul, P., & Shirai, T. (2012a). Kuguacin J, a triterpeniod from Momordica charantia leaf, modulates the progression of androgen-independent human prostate cancer cell line, PC3. Food Chem Toxicol, 50(3-4), 840-847. doi: 10.1016/j.fct.2012.01.009
    Pitchakarn, P., Ohnuma, S., Pintha, K., Pompimon, W., Ambudkar, S.V., & Limtrakul, P. (2012b). Kuguacin J isolated from Momordica charantia leaves inhibits P-glycoprotein (ABCB1)-mediated multidrug resistance. J Nutr Biochem, 23(1), 76-84. doi: 10.1016/j.jnutbio.2010.11.005
    Prestayko, A.W. (2013). Cisplatin: Current Status and New Developments: Elsevier Science.
    Raman, A., & Lau, C. (1996). Anti-diabetic properties and phytochemistry of Momordica charantia L. (Cucurbitaceae). Phytomedicine, 2(4), 349-362. doi: http://dx.doi.org/10.1016/S0944-7113(96)80080-8
    Ray, R.B., Raychoudhuri, A., Steele, R., & Nerurkar, P. (2010). Bitter melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis. Cancer Research, 70(5), 1925-1931.
    Rohwer, N., Dame, C., Haugstetter, A., Wiedenmann, B., Detjen, K., Schmitt, C.A., & Cramer, T. (2010). Hypoxia-Inducible Factor 1α Determines Gastric Cancer Chemosensitivity via Modulation of p53 and NF-κB. PLOS ONE, 5(8), e12038. doi: 10.1371/journal.pone.0012038
    Sadzuka, Y., Hatakeyama, H., Daimon, T., & Sonobe, T. (2008). Screening of biochemical modulator by tumor cell permeability of doxorubicin. International journal of pharmaceutics, 354(1), 63-69.
    Sathishsekar, D., & Subramanian, S. (2005). Antioxidant properties of Momordica Charantia (bitter gourd) seeds on Streptozotocin induced diabetic rats. Asia Pacific journal of clinical nutrition, 14(2), 153.
    Seo, C.-R., Yang, D.K., Song, N.-J., Yun, U.J., Gwon, A.R., Jo, D.-G., Cho, J.Y., Yoon, K., Ahn, J.-Y., Nho, C.W., Park, W.J., Yang, S.Y., & Park, K.W. (2014). Cucurbitacin B and cucurbitacin I suppress adipocyte differentiation through inhibition of STAT3 signaling. Food and Chemical Toxicology, 64, 217-224. doi: http://dx.doi.org/10.1016/j.fct.2013.11.040
    Sethi, G., Ahn, K.S., Pandey, M.K., & Aggarwal, B.B. (2007). Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-κB–regulated gene products and TAK1-mediated NF-κB activation. Blood, 109(7), 2727-2735.
    Shi, W.J., & Gao, J.B. (2016). Molecular mechanisms of chemoresistance in gastric cancer. World J Gastrointest Oncol, 8(9), 673-681. doi: 10.4251/wjgo.v8.i9.673
    Shih, C.-C., Lin, C.-H., & Lin, W.-L. (2008). Effects of Momordica charantia on insulin resistance and visceral obesity in mice on high-fat diet. Diabetes Research and Clinical Practice, 81(2), 134-143. doi: http://dx.doi.org/10.1016/j.diabres.2008.04.023
    Singh, D.K., Upadhyay, A., & Agrahari, P. (2015). A Review on Salient Pharmacological Features of Momordica charantia. International Journal of Pharmacology, 11(5), 405-413. doi: 10.3923/ijp.2015.405.413
    Somasagara, R.R., Deep, G., Shrotriya, S., Patel, M., Agarwal, C., & Agarwal, R. (2015). Bitter melon juice targets molecular mechanisms underlying gemcitabine resistance in pancreatic cancer cells. Int J Oncol, 46(4), 1849-1857. doi: 10.3892/ijo.2015.2885
    Subbaramaiah, K., Michaluart, P., Sporn, M.B., & Dannenberg, A.J. (2000). Ursolic acid inhibits cyclooxygenase-2 transcription in human mammary epithelial cells. Cancer research, 60(9), 2399-2404.
    Sun, L., Liu, L., Liu, X., Wang, Y., Li, M., Yao, L., Yang, J., Ji, G., Guo, C., & Pan, Y. (2014a). Gastric cancer cell adhesion to laminin enhances acquired chemotherapeutic drug resistance mediated by MGr1-Ag/37LRP. Oncology reports, 32(1), 105-114.
    Sun, L., Liu, L., Liu, X., Wang, Y., Li, M., Yao, L., Yang, J., Ji, G., Guo, C., & Pan, Y. (2014b). MGr1‐Ag/37LRP induces cell adhesion‐mediated drug resistance through FAK/PI3K and MAPK pathway in gastric cancer. Cancer science, 105(6), 651-659.
    Svobodova, B., Barros, L., Calhelha, R.C., Heleno, S., Alves, M.J., Walcott, S., Bittova, M., Kuban, V., & Ferreira, I.C.F.R. (2017). Bioactive properties and phenolic profile of Momordica charantia L. medicinal plant growing wild in Trinidad and Tobago. Industrial Crops and Products, 95, 365-373. doi: 10.1016/j.indcrop.2016.10.046
    Tamanoi, F., & Bathaie, S. Z. (2014). Natural products and cancer signaling: isoprenoids, polyphenols and flavonoids (Vol. 36). Academic Press.
    Tan, M.J., Ye, J.M., Turner, N., Ke, C.Q., Tang, C.P., Chen, T., Hohnen-Behrens, C., Rowland, A., James, D.E., & Ye, Y. (2008). New Cucurbitane triterpenoids from bitter melon with potent antidiabetic properties associated with activation of AMPK. Planta Med, 74(09), SL30. doi: 10.1055/s-0028-1083910
    Tan, W., Yu, H.-G., & Luo, H.-S. (2014). Inhibition of the p38 MAPK pathway sensitizes human gastric cells to doxorubicin treatment in vitro and in vivo. Molecular medicine reports, 10(6), 3275-3281.
    Thoennissen, N.H., Iwanski, G.B., Doan, N.B., Okamoto, R., Lin, P., Abbassi, S., Song, J.H., Yin, D., Toh, M., Xie, W.D., Said, J.W., & Koeffler, H.P. (2009). Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Res, 69(14), 5876-5884. doi: 10.1158/0008-5472.CAN-09-0536
    Tian, Z., Yang, M., Huang, F., Li, K., Si, J., Shi, L., Chen, S., & Xiao, P. (2005). Cytotoxicity of three cycloartane triterpenoids from Cimicifuga dahurica. Cancer Lett, 226(1), 65-75. doi: 10.1016/j.canlet.2004.11.019
    Tsai, T.-H., Huang, W.-C., Ying, H.-T., Kuo, Y.-H., Shen, C.-C., Lin, Y.-K., & Tsai, P.-J. (2016). Wild Bitter Melon Leaf Extract Inhibits Porphyromonas gingivalis-Induced Inflammation: Identification of Active Compounds through Bioassay-Guided Isolation. Molecules, 21(4), 454.
    Vyas, D., Laput, G., & Vyas, A.K. (2014). Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis. Onco Targets Ther, 7, 1015-1023. doi: 10.2147/OTT.S60114
    Wang, X., Sun, W., Cao, J., Qu, H., Bi, X., & Zhao, Y. (2012). Structures of new triterpenoids and cytotoxicity activities of the isolated major compounds from the fruit of Momordica charantia L. J Agric Food Chem, 60(15), 3927-3933. doi: 10.1021/jf204208y
    Washington, K. (2010). 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol, 17(12), 3077-3079. doi: 10.1245/s10434-010-1362-z
    Weng, J.-R., Bai, L.-Y., Chiu, C.-F., Hu, J.-L., Chiu, S.-J., & Wu, C.-Y. (2013). Cucurbitane triterpenoid from Momordica charantia induces apoptosis and autophagy in breast cancer cells, in part, through peroxisome proliferator-activated receptor γ activation. Evidence-Based Complementary and Alternative Medicine, 2013.
    Wu, S.-J., & Ng, L.-T. (2008). Antioxidant and free radical scavenging activities of wild bitter melon (Momordica charantia Linn. var. abbreviata Ser.) in Taiwan. LWT - Food Science and Technology, 41(2), 323-330. doi: 10.1016/j.lwt.2007.03.003
    Xiong, S.D., Yu, K., Liu, X.H., Yin, L.H., Kirschenbaum, A., Yao, S., Narla, G., DiFeo, A., Wu, J.B., & Yuan, Y. (2009). Ribosome‐inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase‐1 selectively in premalignant and malignant prostate cancer cells. International journal of cancer, 125(4), 774-782.
    Xu, H.-Y., Xu, W.-L., Wang, L.-Q., Chen, M.-B., & Shen, H.-L. (2014). Relationship between p53 status and response to chemotherapy in patients with gastric cancer: a meta-analysis. PloS one, 9(4), e95371.
    Yadav, V.R., Prasad, S., Sung, B., Kannappan, R., & Aggarwal, B.B. (2010). Targeting inflammatory pathways by triterpenoids for prevention and treatment of cancer. Toxins (Basel), 2(10), 2428-2466. doi: 10.3390/toxins2102428
    Yamaguchi, K., Ishikawa, T., Kondo, Y., & Fujisawa, M. (2008). Cisplatin regulates Sertoli cell expression of transferrin and interleukins. Mol Cell Endocrinol, 283(1-2), 68-75. doi: 10.1016/j.mce.2007.11.021
    Yin, D., Wakimoto, N., Xing, H., Lu, D., Huynh, T., Wang, X., Black, K.L., & Koeffler, H.P. (2008). Cucurbitacin B markedly inhibits growth and rapidly affects the cytoskeleton in glioblastoma multiforme. Int J Cancer, 123(6), 1364-1375. doi: 10.1002/ijc.23648
    Yu, D.-f., Wu, F.-r., Liu, Y., Liu, H., & Xia, Q. (2013). Bcl-2 gene silence enhances the sensitivity toward 5-Fluorouracil in gastric adenocarcinoma cells. Biomedicine & Pharmacotherapy, 67(7), 615-619. doi: http://dx.doi.org/10.1016/j.biopha.2013.03.007
    Yung, M.M., Ross, F.A., Hardie, D.G., Leung, T.H., Zhan, J., Ngan, H.Y., & Chan, D.W. (2015). Bitter Melon (Momordica charantia) Extract Inhibits Tumorigenicity and Overcomes Cisplatin-Resistance in Ovarian Cancer Cells Through Targeting AMPK Signaling Cascade. Integr Cancer Ther. doi: 10.1177/1534735415611747
    Zhang, Zhang, J., Shen, L., Xu, X.-m., & Yu, H.-g. (2013). Overexpression of AKT decreases the chemosensitivity of gastric cancer cells to cisplatin in vitro and in vivo. Molecular medicine reports, 7(5), 1387-1390.
    Zhang, C.Z., Fang, E.F., Zhang, H.T., Liu, L.L., & Yun, J.P. (2015). Momordica charantia lectin exhibits antitumor activity towards hepatocellular carcinoma. Invest New Drugs, 33(1), 1-11. doi: 10.1007/s10637-014-0156-8

    無法下載圖示 本全文未授權公開
    QR CODE